No price history available.
Key financial summary
Financials in JPY| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | ¥m | 51,841 | 51,272 | 61,143 | 62,552 | 63,823 | 64,724 | N/A | N/A |
| Operating profit | ¥m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | ¥m | 5,618 | 6,383 | 7,589 | 7,673 | 7,970 | 8,030 | N/A | N/A |
| EPS reported | ¥ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | ¥ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | ¥ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | ¥ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | ¥m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | ¥m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | ¥m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | ¥ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | ¥ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in JPY| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Noevir Holdings Co., Ltd. is a diversified Japanese conglomerate involved in the creation, production, and distribution of cosmetics, pharmaceuticals, and health food items. Its operations span a wide international footprint, including key markets such as Japan, China, Taiwan, South Korea, Hong Kong, Singapore, Thailand, the United States, Canada, and Russia. The company's Cosmetics division focuses on developing and manufacturing skincare lines, featuring popular brands like Noevir and Nameraka Honpo. It also offers NOV hypoallergenic products and provides contract manufacturing services for cosmetic and quasi-drug formulations. Within its Pharmaceutical & Health Food segment, Noevir produces items such as Nanten Nodo Ame cough drops and functional beverages like Min Min Da Ha. This division also supplies a range of over-the-counter medications, including cold remedies, eye drops, and digestive aids, alongside various nutritional supplements. The "Other" segment broadens the company's scope through the sale and leasing of apparel and aircraft. Furthermore, the company is involved in manufacturing and selling toiletries, procuring and distributing makeup products and containers, and conducting market research. Its extensive aviation services encompass air transport, charter flight operations, ground handling, hanger rentals, and aircraft flight training, in addition to undertaking other aviation-related tasks. Noevir distributes its diverse product portfolio through multiple channels, including pharmacies, specialized retail outlets, general merchandise stores, supermarkets, e-commerce platforms, convenience stores, and a network of approximately 2,000 Noevir beauty studios and proprietary retail locations. Established in Tokyo, Japan, in 1964, Noevir Holdings Co., Ltd. maintains its headquarters there.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Noevir Holdings Co., Ltd. (4928.T)
No price history available.
Based on consensus from external analysts. Not Kvantra's opinion.
Noevir Holdings Co., Ltd. is a diversified Japanese conglomerate involved in the creation, production, and distribution of cosmetics, pharmaceuticals, and health food items. Its operations span a wide international footprint, including key markets such as Japan, China, Taiwan, South Korea, Hong Kong, Singapore, Thailand, the United States, Canada, and Russia. The company's Cosmetics division focuses on developing and manufacturing skincare lines, featuring popular brands like Noevir and Nameraka Honpo. It also offers NOV hypoallergenic products and provides contract manufacturing services for cosmetic and quasi-drug formulations. Within its Pharmaceutical & Health Food segment, Noevir produces items such as Nanten Nodo Ame cough drops and functional beverages like Min Min Da Ha. This division also supplies a range of over-the-counter medications, including cold remedies, eye drops, and digestive aids, alongside various nutritional supplements. The "Other" segment broadens the company's scope through the sale and leasing of apparel and aircraft. Furthermore, the company is involved in manufacturing and selling toiletries, procuring and distributing makeup products and containers, and conducting market research. Its extensive aviation services encompass air transport, charter flight operations, ground handling, hanger rentals, and aircraft flight training, in addition to undertaking other aviation-related tasks. Noevir distributes its diverse product portfolio through multiple channels, including pharmacies, specialized retail outlets, general merchandise stores, supermarkets, e-commerce platforms, convenience stores, and a network of approximately 2,000 Noevir beauty studios and proprietary retail locations. Established in Tokyo, Japan, in 1964, Noevir Holdings Co., Ltd. maintains its headquarters there.
